Information Provided By:
Fly News Breaks for March 28, 2016
PTLA
Mar 28, 2016 | 05:36 EDT
Goldman Sachs analyst Jay Olson downgraded Portola Pharmaceuticals to Neutral after lowering his probability of regulatory/commercial success for betrixaban to 20% from 60% following the APEX topline results. The study missed the first step in the primary analysis plan, Olson tells investors in a research note. The analyst cut his price target for the shares to $30 from $65.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.